



**ANTICANCER AGENT HALAVEN<sup>®</sup> SHOWS SIGNIFICANT EXTENSION IN  
OVERALL SURVIVAL IN PHASE III STUDY ON SOFT TISSUE SARCOMA**

*Phase III data to be presented in a Soft Tissue Sarcoma oral session at ASCO*

3P111c

Eribulin has been designated as an orphan drug for the treatment of soft tissue sarcoma in the United States and Japan.

Eribulin is a halichondrin class microtubule dynamics inhibitor with a novel mechanism of action. It was first approved for the treatment of breast cancer in the United States in November 2010, and is currently approved in approximately 60 countries including Japan and countries in Europe, the Americas and Asia. Through the results of Study 309, eribulin has demonstrated overall survival benefit as a single agent chemotherapy in soft tissue sarcomas as well as metastatic breast cancer, following two prior regimens in the advanced setting.

Based on the results of Study 309, Eisai intends to submit applications during the first half of fiscal 2015 to the regulatory authorities in multiple countries including Japan, the United States and Europe seeking an expansion of the indication for eribulin to include soft tissue sarcoma.

Eisai remains committed to providing further clinical evidence for eribulin aimed at maximizing value of the 0.002 Tw 0